Resistance to Targeted Therapies in Breast Cancer

Description

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. Front Matter ....Pages i-xv Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target? (Georges E. Tanios, Matthew E. Burow, Bridgette Collins-Burow, David G. Morrison)....Pages 1-34 Resistance to HER2-Targeted Therapy (Dirk Theile, Gal Lenz, Jamil A. Momand, Susan E. Kane)....Pages 35-88 Endocrine Resistance and Breast Cancer Stem Cells: The Inflammatory Connection that Could Lead to New and Improved Therapy Outcomes (Irida Kastrati)....Pages 89-101 EGFR Resistance (Laura Bourdeanu, Ellen Liu, Suzanne Brint, David Langdon)....Pages 103-116 Targeting FGFR for the Treatment of Breast Cancer (Remah Ali, Saeed S. Akhand, Michael K. Wendt)....Pages 117-137 Targeted Therapies in Breast Cancer (Anna T. Lyons, Jenifer R. Prosperi)....Pages 139-154 Future Paradigm of Breast Cancer Resistance and Treatment (Ravi Velaga, Masahiro Sugimoto)....Pages 155-178 Back Matter ....Pages 179-184